Investors piled into the debut bond from shire last week, ignoring some clear warning signals that the drugmaker's deal might have offered a little bit less than meets the eye. For months, the buyside has seemed to have more cash than it knows what to do with, a scenario that has propelled the US high-grade primary to issuance record after issuance record.
展开▼
